Farmacologia y Toxicologia

Awards Nomination 20+ Million Readerbase

• JOURNAL HOME
• Editors
Articles
• In Process
• Archive
Authors
• Author Guidelines
• Submit Manuscript
In Detail
• Aim and Scope
• Publication ethics
• Peer Review Process
• Copyright
• Citations
• Contact Us

A Case Report on Danger of Improperly Approved Drugs

Ujvyid Tanyehi^* Department of Industrial and Systems Engineering, North Carolina State University, Raleigh, NC 27606, USA
^*Correspondence: Ujvyid Tanyehi, Department of Industrial and Systems Engineering, North Carolina State University, Raleigh, NC 27606, USA, Email:

Received: 03-Apr-2023, Manuscript No. ipft-23-13647; Editor assigned: 05-Apr-2023, Pre QC No. P-13647; Reviewed: 19-Apr-2023, QC No. Q-13647; Revised: 22-Apr-2023, Manuscript No. R-13647; Published: 28-Apr-2023

Introduction

The pharmaceutical industry is a critical aspect of modern healthcare, providing drugs that help treat and prevent diseases. However, the process of developing and approving drugs is complex and requires extensive testing, research, and quality control measures [1]. Unfortunately, there have been instances where drugs have been approved without proper quality control measures, resulting in serious harm to patients. In this article, we explore the damages that can arise when drugs are not properly composed and approved without quality checks. We will discuss the health risks, financial burdens, legal consequences, public health concerns, and loss of trust that can occur, and we will provide suggestions for preventing such cases. It is essential for drug companies and regulatory agencies to prioritize quality control measures to ensure that drugs are safe and effective for patients. The pharmaceutical industry is responsible for providing safe and effective drugs that help treat and prevent various diseases [2]. However, the process of developing and approving drugs is a complex and rigorous one, requiring extensive testing, research, and quality control measures to ensure that the drugs are safe and effective.

Discussion

Unfortunately, there have been cases where drugs have been approved without proper quality control measures, resulting in serious harm to patients [3]. If a drug is not properly composed and then approved without quality checks, it can cause a wide range of damages, including:

1. Health risks: Drugs that are not properly composed and tested can have serious health risks. This can include adverse side effects, drug interactions, and even death. Patients may experience symptoms such as headaches, nausea, vomiting, dizziness, seizures, and other serious complications.

2. Financial burden: Patients who are harmed by a drug that was not properly composed and approved may face significant financial burdens. This can include medical bills, lost wages, and other expenses related to the treatment and recovery process.

3. Legal consequences: Drug companies that fail to properly test and control the quality of their drugs may face legal consequences. This can include lawsuits, fines, and even criminal charges in some cases.

4. Public health concerns: When a drug is approved without proper quality control measures, it can become a public health concern. This can lead to widespread outbreaks of disease and other serious health problems.

5. Loss of trust: When a drug company fails to properly test and control the quality of their drugs, it can lead to a loss of trust in the pharmaceutical industry. This can make it difficult for other drug companies to gain the trust of patients and healthcare providers, leading to a decline in the overall quality of care [4, 5].

To prevent drugs from being approved without proper quality control measures, there are several steps that can be taken:

1. Strengthen regulations: Regulatory agencies such as the FDA can strengthen their regulations to ensure that drugs are properly tested and that quality control measures are in place. This can include more rigorous testing requirements, more frequent inspections, and increased penalties for companies that fail to comply with regulations.

2. Increase transparency: Drug companies can increase transparency by providing more information about the development and testing of their drugs. This can include publishing research studies, providing detailed information about the manufacturing process, and making information about adverse events public.

3. Improve communication: Healthcare providers can improve communication with their patients by discussing the risks and benefits of medications and encouraging patients to report any adverse events or side effects. This can help identify potential problems early and prevent harm to patients.

4. Promote research: Funding research on the safety and efficacy of drugs can help identify potential problems before they become widespread. This can include research on drug interactions, long-term effects, and the safety of medications in specific populations such as pregnant women or children.

5. Educate the public: Educating the public about the importance of proper quality control measures can help raise awareness and prevent harm. This can include providing information about the regulatory process, the risks and benefits of medications, and the importance of reporting adverse events [6, 7].

To be more efficient in preventing drugs from being approved without proper quality control measures, it is essential to prioritize quality control measures throughout the drug development and approval process. This can include:

Investing in Research and Development: Drug companies can invest in research and development to identify potential problems early on and ensure that drugs are safe and effective for patients Conducting Rigorous Testing: Regulatory agencies can require more rigorous testing to ensure that drugs are safe and effective before they are approved for use [8]. Increasing Transparency: Drug companies can increase transparency by providing more information about the development and testing of their drugs, including the manufacturing process, research studies, and adverse event reports Improving Communication: Healthcare providers can improve communication with their patients by discussing the risks and benefits of medications and encouraging patients to report any adverse events or side effects. Collaborating with Regulatory Agencies: Drug companies and regulatory agencies can work together to identify potential problems and ensure that quality control measures are in place throughout the drug development and approval process [9, 10].

By prioritizing quality control measures and collaborating across the industry, we can be more efficient in preventing drugs from being approved without proper quality control measures and ensuring that drugs are safe and effective for patients.

Conclusion

In conclusion, the approval of drugs without proper quality control measures can have serious and far-reaching consequences. Patients who are harmed by these drugs may suffer from serious health risks, financial burdens, and legal consequences, while the pharmaceutical industry may face public health concerns and a loss of trust. It is essential for drug companies and regulatory agencies to prioritize quality control measures to ensure that drugs are safe and effective for patients.

Preventing drugs from being approved without proper quality control measures requires a collaborative effort from regulatory agencies, drug companies, healthcare providers, researchers, and the public. By strengthening regulations, increasing transparency, improving communication, promoting research, and educating the public, we can help ensure that drugs are safe and effective for patients.

Acknowledgement

None

Conflict of Interest

No conflict of interest to declare about this work.

References

1. Tomlin JL, Sturgeon C, Pead MJ, et al. Use of the bisphosphonate drug alendronate for palliative management of osteosarcoma in two dogs. Vet Rec.2000:147(2): 129-32.

Indexed at, Google Scholar, Crossref

2. Psychas V, Loukopoulos P, Polizopoulou ZS, et al. Multilobular tumour of the caudal cranium causing severe cerebral and cerebellar compression in a dog. J Vet Sci. 2009; 10(5): 81-3.

Indexed at, Google Scholar, Crossref

3. Loukopoulos P, Thornton JR, Robinson WF. Clinical and pathologic relevance of p53 index in canine osseous tumors. Veterinary Pathology.2003; 40(8): 237-48.

Indexed at, Google Scholar, Crossref

4. Bech-Nielsen S, Haskins ME. Frequency of osteosarcoma among first-degree relatives of St Bernard dogs. J Natl Cancer Inst.2003;60(4): 349-53.

Indexed at, Google Scholar, Crossref

5. Wilkins RM, Cullen JW, Odom L. Superior survival in treatment of primary nonmetastatic pediatric osteosarcoma of the extremity. Ann Surg Oncol.2003; 10(4): 498-507.

Indexed at, Google Scholar, Crossref

6. Kundu ZS. Classification, imaging, biopsy and staging of osteosarcoma. Indian J Orthop.2014;48(2): 238-46.

Indexed at, Google Scholar, Crossref

7. Papalas JA, Balmer NN, Wallace C. Ossifying dermatofibroma with osteoclast-like giant cells: report of a case and literature review. Am J Dermatopathol.2009; 31(5): 379-83.

Indexed at, Google Scholar, Crossref

8. Gelberg KH, Fitzgerald EF, Hwang SA. Fluoride exposure and childhood osteosarcoma: a case-control study. Am J Public Health.1995; 85(2): 1678-83.

Indexed at, Google Scholar, Crossref

9. Luetke A, Meyers PA, Lewis A. Osteosarcoma treatment where do we stand a state of the art review. Cancer Treat Rev. 2014; 40(5): 523-532.

Indexed at, Google Scholar, Crossref

10. Dhaliwal J, Sumathi VP, Grimer RJ. Radiation-induced periosteal osteosarcoma (PDF). Grand Rounds.2009;10(1): 13-18.

Indexed at, Google Scholar, Crossref